Global Tofacitinib Tablets 麻豆原创 Growth 2025-2031

Publication ID:

LPI04254549

Publication Date:

April 23, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Tofacitinib Tablets market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Tofacitinib, also known as Xeljanz, is听a type of drug known as a Janus kinase (JAK) inhibitor. It works by blocking the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of rheumatoid arthritis and psoriatic arthritis.
United States market for Tofacitinib Tablets is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Tofacitinib Tablets is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Tofacitinib Tablets is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Tofacitinib Tablets players cover Pfizer, Globe Pharmaceuticals, Delta Pharma Limited, Beacon Pharmaceuticals, Drug International, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淭ofacitinib Tablets Industry Forecast鈥� looks at past sales and reviews total world Tofacitinib Tablets sales in 2024, providing a comprehensive analysis by region and market sector of projected Tofacitinib Tablets sales for 2025 through 2031. With Tofacitinib Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tofacitinib Tablets industry.
This Insight Report provides a comprehensive analysis of the global Tofacitinib Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tofacitinib Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Tofacitinib Tablets market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tofacitinib Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tofacitinib Tablets.
This report presents a comprehensive overview, market shares, and growth opportunities of Tofacitinib Tablets market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
5mg*60 Tablets
5mg*10 Tablets
10mg*10 Tablets
5mg*30 Tablets
5mg*14 Tablets
10mg*14 Tablets
Segmentation by Application:
Rheumatoid Arthritis
Ulcerative Colitis
Psoriasis
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Globe Pharmaceuticals
Delta Pharma Limited
Beacon Pharmaceuticals
Drug International
Key Questions Addressed in this Report
What is the 10-year outlook for the global Tofacitinib Tablets market?
What factors are driving Tofacitinib Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tofacitinib Tablets market opportunities vary by end market size?
How does Tofacitinib Tablets break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Tofacitinib Tablets Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Tofacitinib Tablets by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Tofacitinib Tablets by Country/Region, 2020, 2024 & 2031
2.2 Tofacitinib Tablets Segment by Type
2.2.1 5mg*60 Tablets
2.2.2 5mg*10 Tablets
2.2.3 10mg*10 Tablets
2.2.4 5mg*30 Tablets
2.2.5 5mg*14 Tablets
2.2.6 10mg*14 Tablets
2.3 Tofacitinib Tablets Sales by Type
2.3.1 Global Tofacitinib Tablets Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Tofacitinib Tablets Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Tofacitinib Tablets Sale Price by Type (2020-2025)
2.4 Tofacitinib Tablets Segment by Application
2.4.1 Rheumatoid Arthritis
2.4.2 Ulcerative Colitis
2.4.3 Psoriasis
2.4.4 Other
2.5 Tofacitinib Tablets Sales by Application
2.5.1 Global Tofacitinib Tablets Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Tofacitinib Tablets Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Tofacitinib Tablets Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Tofacitinib Tablets Breakdown Data by Company
3.1.1 Global Tofacitinib Tablets Annual Sales by Company (2020-2025)
3.1.2 Global Tofacitinib Tablets Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Tofacitinib Tablets Annual Revenue by Company (2020-2025)
3.2.1 Global Tofacitinib Tablets Revenue by Company (2020-2025)
3.2.2 Global Tofacitinib Tablets Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Tofacitinib Tablets Sale Price by Company
3.4 Key Manufacturers Tofacitinib Tablets Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tofacitinib Tablets Product Location Distribution
3.4.2 Players Tofacitinib Tablets Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Tofacitinib Tablets by Geographic Region
4.1 World Historic Tofacitinib Tablets 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Tofacitinib Tablets Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Tofacitinib Tablets Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Tofacitinib Tablets 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Tofacitinib Tablets Annual Sales by Country/Region (2020-2025)
4.2.2 Global Tofacitinib Tablets Annual Revenue by Country/Region (2020-2025)
4.3 Americas Tofacitinib Tablets Sales Growth
4.4 APAC Tofacitinib Tablets Sales Growth
4.5 Europe Tofacitinib Tablets Sales Growth
4.6 Middle East & Africa Tofacitinib Tablets Sales Growth
5 Americas
5.1 Americas Tofacitinib Tablets Sales by Country
5.1.1 Americas Tofacitinib Tablets Sales by Country (2020-2025)
5.1.2 Americas Tofacitinib Tablets Revenue by Country (2020-2025)
5.2 Americas Tofacitinib Tablets Sales by Type (2020-2025)
5.3 Americas Tofacitinib Tablets Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tofacitinib Tablets Sales by Region
6.1.1 APAC Tofacitinib Tablets Sales by Region (2020-2025)
6.1.2 APAC Tofacitinib Tablets Revenue by Region (2020-2025)
6.2 APAC Tofacitinib Tablets Sales by Type (2020-2025)
6.3 APAC Tofacitinib Tablets Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Tofacitinib Tablets by Country
7.1.1 Europe Tofacitinib Tablets Sales by Country (2020-2025)
7.1.2 Europe Tofacitinib Tablets Revenue by Country (2020-2025)
7.2 Europe Tofacitinib Tablets Sales by Type (2020-2025)
7.3 Europe Tofacitinib Tablets Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tofacitinib Tablets by Country
8.1.1 Middle East & Africa Tofacitinib Tablets Sales by Country (2020-2025)
8.1.2 Middle East & Africa Tofacitinib Tablets Revenue by Country (2020-2025)
8.2 Middle East & Africa Tofacitinib Tablets Sales by Type (2020-2025)
8.3 Middle East & Africa Tofacitinib Tablets Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tofacitinib Tablets
10.3 Manufacturing Process Analysis of Tofacitinib Tablets
10.4 Industry Chain Structure of Tofacitinib Tablets
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tofacitinib Tablets Distributors
11.3 Tofacitinib Tablets Customer
12 World Forecast Review for Tofacitinib Tablets by Geographic Region
12.1 Global Tofacitinib Tablets 麻豆原创 Size Forecast by Region
12.1.1 Global Tofacitinib Tablets Forecast by Region (2026-2031)
12.1.2 Global Tofacitinib Tablets Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Tofacitinib Tablets Forecast by Type (2026-2031)
12.7 Global Tofacitinib Tablets Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Tofacitinib Tablets Product Portfolios and Specifications
13.1.3 Pfizer Tofacitinib Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Globe Pharmaceuticals
13.2.1 Globe Pharmaceuticals Company Information
13.2.2 Globe Pharmaceuticals Tofacitinib Tablets Product Portfolios and Specifications
13.2.3 Globe Pharmaceuticals Tofacitinib Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Globe Pharmaceuticals Main Business Overview
13.2.5 Globe Pharmaceuticals Latest Developments
13.3 Delta Pharma Limited
13.3.1 Delta Pharma Limited Company Information
13.3.2 Delta Pharma Limited Tofacitinib Tablets Product Portfolios and Specifications
13.3.3 Delta Pharma Limited Tofacitinib Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Delta Pharma Limited Main Business Overview
13.3.5 Delta Pharma Limited Latest Developments
13.4 Beacon Pharmaceuticals
13.4.1 Beacon Pharmaceuticals Company Information
13.4.2 Beacon Pharmaceuticals Tofacitinib Tablets Product Portfolios and Specifications
13.4.3 Beacon Pharmaceuticals Tofacitinib Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Beacon Pharmaceuticals Main Business Overview
13.4.5 Beacon Pharmaceuticals Latest Developments
13.5 Drug International
13.5.1 Drug International Company Information
13.5.2 Drug International Tofacitinib Tablets Product Portfolios and Specifications
13.5.3 Drug International Tofacitinib Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Drug International Main Business Overview
13.5.5 Drug International Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.